We thank Akiyama et al. ([@R1]) for providing evidence in support of our data demonstrating the importance of circulating-activated (PD1+CXCR5+CD4+) and tissue-resident (CXCR5+CD4+) T follicular helper (Tfh) cells in patients with IgG4-related disease (IgG4-RD) and the role of Tfh cells supporting B cells to differentiate into plasmablasts to produce IgG4 antibodies ([@R2]). They highlight important unresolved issues, specifically drivers for Tfh cell expansion in patients with IgG4-RD.

We wish to highlight the presence of a unique subset of circulating T peripheral helper (Tph PD1^hi^CXCR5-CD4+) cells in IgG4-RD, which may be able to recruit both Tfh cells and B cells to the sites of inflammation. Pathologically expanded Tph cells were recently identified in the circulation and nonlymphoid rheumatoid joints in patients with rheumatoid arthritis ([@R3]), and expressed factors including IL21, CXCL13, and inducible co-stimulatory molecule, enabling B cell help. Here, we show for the first time an increase in the percentage of circulating PD1^hi^CXCR5-CD4+ Tph cells in patients with active IgG4-related pancreatic and biliary disease compared with treated inactive disease (*P* = 0.002) and healthy volunteers (*P* = 0.04) (Figure [1](#F1){ref-type="fig"}, top panels). The percentage of Tph cells correlates with the serum IgG4 level (*P* = 0.02, r0.75) and IgG4-responder disease activity index (*P* = 0.003, r = 0.71) (Figure [1](#F1){ref-type="fig"}, bottom panels). The absolute number of circulating Tph cells falls with corticosteroid treatment (*P* = 0.03). We have demonstrated coexpression of CD4+ T cells with CXCL13, a ligand of CXCR5, and inducible co-stimulatory molecule in affected tissues (pancreas, bile duct, and salivary gland) in IgG4-RD ([@R2]).

![Circulating Tph cells in IgG4-RD. Top left panel shows gating strategy to identify PD1+CXCR5-CD4+ Tph cells. Top Right panel shows Tph cells (PD1+) as a percentage of CXCR5- CD4+CD45RA cells in patients with active IgG4-RD (n = 11), inactive IgG4-RD (n = 5), and healthy controls (n = 9). Median and interquartile range shown. Mann--Whitney nonparametric test and Kruskal--Wallis test with Dunn correction for multiple comparisons between groups \**P* \< 0.05; \*\**P* \< 0.01. Bottom Left panel shows the spearman rank correlation between serum IgG4 (log10) and percentage of Tph cells in IgG4-RD (*P* = 0.02; r = 0.75). Bottom Right panel shows the spearman rank correlation between IgG4-responder index disease activity score and percentage of Tph cells in IgG4-RD (*P* = 0.003; r = 0.71). IgG4-RD, IgG4-related disease; Tph, T peripheral helper.](ct9-11-e00111-g001){#F1}

Expanded Tph cells can express chemokine receptors that direct migration to inflamed sites, such as CCR2 and CCR5, and chemokines such as CXCL13, which may recruit CXCR5-expressing immune cells, including Tfh cells and B cells to initiate and maintain inflammation ([@R4]). As such, Tph cells may play a more pathogenic role than their Tfh counterparts in IgG4-RD immune pathogenesis. Key questions remain in the developmental relationship, origin, and differentiation of such cells in the context of IgG4-RD. Understanding the mechanisms underlying Tfh and Tph cell-mediated immunity and pathology may bring potential targets for novel therapies in this disease.
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